Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native ...

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native ...

Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk ...

Novo Nordisk ends partnership with Hims & Hers over compounded Wegovy, shaking the market. See why I recommend a wait-and-see ...

Fintel reports that on June 23, 2025, HC Wainwright & Co. initiated coverage of Septerna (NasdaqGM:SEPN) with a Buy ...

Analysts have set 12-month price targets for Septerna, revealing an average target of $20.0, a high estimate of $26.00, and a low estimate of $11.00. Witnessing a positive shift, the current average ...